Cardiovascular Benefits of Omega-3 Polyunsaturated Fatty Acids: Volume 7 Solvay Pharmaceuticals Conferences PDF
Preview Cardiovascular Benefits of Omega-3 Polyunsaturated Fatty Acids: Volume 7 Solvay Pharmaceuticals Conferences
CARDIOVASCULAR BENEFITS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS Solvay Pharmaceuticals Conferences Series Editors Werner Cautreels, Claus Steinborn and Lechoslaw Turski Volume 7 Previously published in this series Vol. 6 B. Testa and L. Turski (Eds.), Virtual ADMET Assessment in Target Selection and Maturation Vol. 5 C.G. Kruse, H.Y. Meltzer, C. Sennef and S.V. van de Witte (Eds.), Thinking About Cognition: Concepts, Targets and Therapeutics Vol. 4 J. Antel, N. Finer, D. Heal and G. Krause (Eds.), Obesity and Metabolic Disorders Vol. 3 G. Krause, J.R. Malagelada and U. Preuschoff (Eds.), Functional Disorders of the Gastrointestinal Tract Vol. 2 J.G. Papp, M. Straub and D. Ziegler (Eds.), Atrial Fibrillation: New Therapeutic Concepts Vol. 1 E. Ronken and G.J.M. van Scharrenburg (Eds.), Parkinson’s Disease ISSN 1566-7685 Cardiovascular Benefits of Omega-3 Polyunsaturated Fatty Acids Edited by B. Maisch Philipps University of Marburg, Marburg, Germany and R. Oelze Solvay Pharmaceuticals, Hannover, Germany Amsterdam • Berlin • Oxford • Tokyo • Washington, DC © 2006 The authors. All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without prior written permission from the publisher. ISBN 978-1-58603-707-9 Library of Congress Control Number: 2006939183 Publisher IOS Press Nieuwe Hemweg 6B 1013 BG Amsterdam Netherlands fax: +31 20 687 0019 e-mail: [email protected] Distributor in the UK and Ireland Distributor in the USA and Canada Gazelle Books Services Ltd. IOS Press, Inc. White Cross Mills 4502 Rachael Manor Drive Hightown Fairfax, VA 22032 Lancaster LA1 4XS USA United Kingdom fax: +1 703 323 3668 fax: +44 1524 63232 e-mail: [email protected] e-mail: [email protected] LEGAL NOTICE The publisher is not responsible for the use which might be made of the following information. PRINTED IN THE NETHERLANDS Cardiovascular Benefits of Omega-3 Polyunsaturated Fatty Acids v B. Maisch and R. Oelze (Eds.) IOS Press, 2006 © 2006 The authors. All rights reserved. Preface “The Solvay Pharmaceutical Conferences: where industry meets academia in a search for novel therapies” Therapy for Sudden Death Still Awaited During the last decades progress has been made in the treatment of patients who survived myocardial infarction. The implementation of coronary care units and evolution of public education to encourage rapid response, development of catheter-based revascularization techniques, greater emphasis on cardiac rehabilitation, and improved therapy have contributed to improvement of prognosis for patients with myocardial infarction. The introduction of aspirin, thrombolytics, ß-blockers, ACE-inhibitors and statins led to reduction in both short-term and immediate mortality rates among patients suffering from myocardial infarction. Nevertheless, patients who survive an acute myocardial infarction are at high risk, with life expectancy half that of their peers who have not experienced similar events, and with increased risk for subsequent cardiovascular events and death. The risk of sudden death increases with severity of systolic dysfunction after myocardial infarction. Sudden death has proved to be more difficult to treat than coronary disease. In recent years, it has become clear that in addition to risk factors such as overweight, lack of exercise, smoking, hypertension and hypercholesterolemia, psychosocial factors play a key role for prognosis in patients with myocardial infarction. Depression, anxiety, perceived social support and social desirability may have an effect on mortality and morbidity in such patients. Therefore, there is high medical need for drugs which lower the incidence of sudden death and have an effect on other risk factors such as depression. A pharmaceutical preparation of highly purified and concentrated (cid:58)-3 polyunsaturated acids, OMACOR®, may represent such a drug. It lowers the incidence of sudden death in patients with myocardial infarction and decreases depression. This volume summarizes lectures delivered during the symposium entitled “Effect of (cid:58)-3 polyunsaturated fatty acids on different risk factors in patients with cardiovascular disease” presented during the European Cardiology Society Congress in Stockholm (Sweden) in 2005. In addition, aspects of prevention of cardiovascular disease, risk factors, and pharmacokinetics of (cid:58)-3 fatty acids ethyl esters have been considered. W. Cautreels C. Steinborn L. Turski This page intentionally left blank vii List of Contributors Alter, P. Molecular Cardiology Laboratory, Department of Internal Medicine and Cardiology, Philipps University of Marburg, Karl-von-Frisch-Strasse 1, D-35033 Marburg, Germany Annemans, L. HEDM-IMS, Rue De Crayer 6, 1000 Brussels, Belgium Ghent University, Sint-Pietersnieuwstraat 25, 9000 Ghent, Belgium Cautreels, W. Solvay Pharmaceuticals, Brussels, Belgium Connolly, S.J Faculty of Health Sciences, McMaster University, 237 Barton Street E., Hamilton, Ontario L8L 2X2, Canada Frasure-Smith, N. Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Recherche Psychiatrie, Pavillon L-C Simard, 1560 rue Sherbrooke Est, Montréal, Québec, Canada H2L 4M1 Healey, J.S. Faculty of Health Sciences, McMaster University, 237 Barton Street E., Hamilton, Ontario L8L 2X2, Canada Huber, G. 1st Medical Department, SMZ-Ost/Danube Hospital, Langobardenstrasse 122, A-1220 Vienna, Austria Kawalec, P. HTA Center, Nuszkiewicza Street 13/19, Krakow, Poland Institute of Public Health, Collegium Medium, Jagiellonian University, Grzegorzecka Street 20, Krakow, Poland Lamotte, M. HEDM-IMS, Rue De Crayer 6, 1000 Brussels, Belgium Lespérance, F. Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Recherche Psychiatrie, Pavillon L-C Simard, 1560 rue Sherbrooke Est, Montréal, Québec, Canada H2L 4M1 viii Maisch, B. Molecular Cardiology Laboratory, Department of Internal Medicine and Cardiology, Philipps University of Marburg,Baldingerstrasse, D-35043 Marburg, Germany Rupp, H. Molecular Cardiology Laboratory, Department of Internal Medicine and Cardiology, Philipps University of Marburg, Karl-von-Frisch-Strasse 1, D-35033 Marburg, Germany Rupp, T.P. Molecular Cardiology Laboratory, Department of Internal Medicine and Cardiology, Philipps University of Marburg, Karl-von-Frisch-Strasse 1, D-35033 Marburg, Germany Selimi, D. 1st Medical Department, SMZ-Ost/Danube Hospital, Langobardenstrasse 122, A-1220 Vienna, Austria Severus, W.E. Ludwig-Maximilians-University, Department of Psychiatry, Nußbaumstrasse 7, 80336 Munich, Germany Steinborn, C. Solvay Pharmaceuticals, Hannover, Germany Turski, L. Solvay Pharmaceuticals, Weesp, The Netherlands Verboom, C.N. Solvay Pharmaceuticals, Hannover, Germany Vik, H. Pronova Biocare, P.O. Box 420, N-1327 Lysaker, Norway Vinereanu, D. University of Medicine and Pharmacy Carol Davila, Cardiology, University Hospital of Bucharest, Splaiul Independentei 169, Bucharest, 05098, Romania Wagner, D. Molecular Cardiology Laboratory, Department of Internal Medicine and Cardiology, Philipps University of Marburg, Karl-von-Frisch-Strasse 1, D-35033 Marburg, Germany Weber, H.S. 1st Medical Department, SMZ-Ost/Danube Hospital, Langobardenstrasse 122, A-1220 Vienna, Austria Zoellner, Y. Solvay Pharmaceuticals GmbH, Global Health Economics, P.O. Box 220, D-30002 Hannover, Germany ix Contents Preface v W. Cautreels, C. Steinborn and L. Turski List of Contributors vii Conference Preface 3 Bernhard Maisch Keynote Lecture – Risk Factors for Atherosclerotic Disease: Present and Future 7 Dragos Vinereanu Microdetermination of Fatty Acids by Gas Chromatography and Cardiovascular Risk Stratification by the “EPA+DHA Level” 47 Heinz Rupp, Thomas P. Rupp, Daniela Wagner, Peter Alter and Bernhard Maisch Highly Purified Omega-3 Polyunsaturated Fatty Acids Are Effective as Adjunct Therapy for Secondary Prevention of Myocardial Infarction: Critical Analysis of GISSI-Prevenzione Trial 81 Cees N. Verboom Prevention of Cardiovascular Diseases and Highly Concentrated n-3 Polyunsaturated Fatty Acids (PUFAs) 99 Heinz S. Weber, Dzevair Selimi and Gustav Huber Omega-3 Fatty Acids and Sudden Arrhythmic Death 111 Stuart J. Connolly and Jeffrey S. Healey Depression and Coronary Artery Disease: Epidemiology and Potential Mechanisms 121 Nancy Frasure-Smith and François Lespérance Effects of Omega-3 Polyunsaturated Fatty Acids on Depression 129 W. Emanuel Severus A Multi-Country Health-Economic Evaluation of Highly Concentrated n-3 Polyunsaturated Fatty Acids (PUFAs) in the Secondary Prevention After Myocardial Infarction (MI) 139 Mark Lamotte, Lieven Annemans, Pawel Kawalec and York Zoellner ® OMACOR in Clinical Development: A Survey of Current Trials 155 Hogne Vik Author Index 185 This page intentionally left blank
Description:The list of books you might like
